Answers are grounded in this paper and cite their sources.
This review explores tumor progression in retinoblastoma and highlights biomarker potential of long non-coding RNAs, indicating significant challenges ahead.
Retinoblastoma (RB) is a primary cancer of the eye that predominantly affects children, although rare adult cases have been reported. This malignancy arises from immature retinal cells and is a major cause of vision loss in the pediatric population. In advanced stages, RB can spread to the brain and other organs. The primary driver of this disease is mutations in the RB1 tumor suppressor gene; however, the full development and advancement of RB necessitate further genetic and epigenetic changes beyond RB1 inactivation. Epigenetic alterations in RB involve various mechanisms, with non-coding RNAs (ncRNAs) playing a crucial role in tumor progression. Dysregulation of various ncRNA classes, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), has been extensively documented, highlighting their contribution to the complexity and progression of the disease. The present study aims to collect a series of previously published studies exploring the contribution of ncRNAs in RB and their potential application as diagnostic and prognostic biomarkers, as well as considering them as valuable targets in the treatment of RB. It will also address the challenges encountered during this pathway.
No takes yet. Share an insight, caveat, or question.
Azani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: